Featuring MicroValve design, the Provent sleep apnea therapy uses nasal expiratory positive airway pressure to keep a patient’s airway open during sleep which otherwise can collapse and lead to fatigue, early morning headaches, irritability, depression, learning and memory difficulties, and sexual dysfunction.

The company said recent studies have also shown that OSA is associated with high blood pressure, irregular heartbeat, heart attack, stroke and diabetes.

Ventus Medical chief medical officer Philip Westbrook said the company believes that the clinically-proven Provent therapy is an alternative to continuous positive airway pressure treatment for the large number of people affected by OSA in Canada.

"Provent has been used effectively in the United States since 2008 and in clinical studies, Provent Therapy improved quality of sleep while it reduced apnea (breathing disruptions), daytime sleepiness and snoring," Westbrook added.

"Importantly, Provent is easy to use, portable and discreet for use at home or when travelling."

The company said its Provent therapy will be made available throughout Canada in June 2013 by its distribution partner, ioSleep.